Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2820-2827

  Pipas, J M ^a   Zaki, B I ^a   Mcgowan, M M ^a   Tsapakos, M J ^a   Ripple, G H ^a   Suriawinata, A A ^a   Tsongalis, G J ^a   Colacchio, T A ^a   Gordon, S R ^a   Sutton, J E ^b   Srivastava, A ^c   Smith, K D ^a   Gardner, T B ^a   Korc, M ^d   Davis, T H ^a   Preis, M ^a   Tarczewski, S M ^e   Mackenzie, T A ^a   Barth, R J ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b VA MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Cetuximab; Gemcitabine; Intensity modulated radiotherapy; Neoadjuvant therapy; Pancreatic cancer

Indexed keywords

EID: 84868101159     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds109     Document Type: Article

References (33)

1. Horner MJ, Ries LAG, Krapcho M et al. (eds). Adenocarcinoma of the Pancreas, in SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute 2009.
2. Staley CA, Lee JE, Cleary KR et al.. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171: 118-124; discussion 124-125.
3. Shewach DS, Lawrence TS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 1995; 22: 68-71.
4. Pipas JM, Mitchell SE, Barth RJ et al.. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001; 50: 1317-1322.
5. Pipas JM, Barth RJ, Zaki B et al.. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005; 12: 995-1004.
6. Mendelsohn J, Baird A, Fan Z et al.. Growth factors and their receptors in epithelial malignancies. In Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds). The Molecular Basis of Cancer. Philadelphia, PA: W.B. Saunders Company 2001; 137-144.
7. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999; 17: 259-269.
8. Uegaki K, Nio Y, Inoue Y. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997; 17: 3841-3847.
9. Korc M, Chandrasekar B, Yamanaka Y et al.. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin Invest 1992; 90: 1352-1360.
10. Abbruzzese JL, Rosenberg A, Xiong Q et al.. "Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Cetuximab (IMC-C225) in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer". Proceedings of American Society of Clinical Oncology 2001; 20: 518.
11. Yamanaka Y, Friess H, Kobrin MS et al.. Coexpression of epidermal growth factor receptor and its ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993; 13: 565-569.
12. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18: 427-436.
13. Bruns CJ, Harbison MT, Davis DW et al.. Epidermal growth factor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
14. Overholser JP, Prewett MC, Hooper AT et al.. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89: 74-82.
15. Liang K, Ang KK, Milas L et al.. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57: 246-254.
16. Buchsbaum DJ, Bonner JA, Grizzle WE et al.. Treatment of pancreatic cancer xenografts with erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54: 1180-1193.
17. Callery MP, Chang KJ, Fishman EK et al.. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
18. Therasse P, Arbuck SG, Eisenhauer EA et al.. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cance Inst 2000; 92: 205-211.
19. Evans DB, Rich TA, Byrd D et al.. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
20. Berger AC, Farma J, Scott W et al.. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337.
21. Maas M, Nelemans PJ, Vanentini V et al.. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844.
22. Preis M, Korc M. Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biol Ther 2010; 9: 1-10.
23. Schwartz MA, Ginsberg MH. Network and crosstalk: integrin signalling spreads. Nat Cell Biol 2002; 4: 65-68.
24. Boulay BR, Gardner TB, Gordon SR. Occlusion rate and complications of plastic biliary stent placement in patients undergoing neoadjuvant chemoradiotherapy for pancreatic cancer with malignant biliary obstruction. J Clini Gastroenterol 2010; 44: 452-455.
25. Herman JM, Swartz MJ, Hsu CC et al.. Analysis of fluorouracil-based chemotherapy and radiation after pancreaticoduodonectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at The Johns Hopkins Hospital. J Clin Oncol 2008; 21: 3503-3510.
26. Corsini MM, Miller RC, Haddock MG et al.. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic Experience (1975-2005). J Clin Oncol 2008; 21: 3511-3516.
27. Cheng TY, Sheth K, White RR et al.. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol 2006; 13: 66-74.
28. Cheng TY, Sheth K, White RR et al.. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009; 38: 282-288.
29. Greer SE, Pipas JM, Sutton JE et al.. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008; 206: 451-457.
30. Gillen S, Schuster T, Meyer zum Buschenfelde C et al.. Preoperative/Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7.
31. Morgan MA, Parsels LA, Maybaum J et al.. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008; 14: 6744-6750.
32. Morgan MA, Parsels LA, Kollar LE et al.. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14: 5142-5149.
33. Conroy T, Desseigne F, Ychou M et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.